Oxcia AB Publishes Annual Report for 2025

Oxcia AB Publishes Annual Report for 2025 Mon, May 25, 2026 09:57 CET Report this content Oxcia AB (publ) (“Oxcia”) today announced the publication of its Annual Report for 2025. Oxcia’s Annual Report is available (in swedish) at https://oxcia.com/investor/finansiella-rapporter/. In the report, CEO Ulrika Warpman Berglund comments: “2025 was the year in which Oxcia secured its first collaboration agreement with a global pharmaceutical company, as well as ODD from the two largest regulatory authorities.” The Annual General Meeting will be held on June 17, 2026, 16:30, at Fogdevreten 2, Solna. For more information contact: Ulrika Warpman Berglund, CEO, Oxcia AB (publ) Telephone: +46 (0) 73 270 9605 ulrika.warpmanberglund@oxcia.com Briefly about Oxcia AB Oxcia’s aim is to improve and extend lives by developing new innovative treatments based on our unique technology platform, O2-DDR . Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe and effective treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two O2-DDR lead drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against idiopathic pulmonary fibrosis, and is in the preclinical phase. The portfolio also includes exploratory projects, e.g in psoriasis. More information about Oxcia is available at www.oxcia.com